Xeris Biopharma Holdings Q3 EPS $(0.09) Vs. $(0.16) Last Year, Sales $48.32M Beat $41.08M Estimate
Portfolio Pulse from Benzinga Newsdesk
Xeris Biopharma Holdings reported Q3 losses of $(0.09) per share, a 43.75% increase over last year. The company's quarterly sales were $48.32 million, beating the analyst consensus estimate of $41.08 million by 17.62%, and marking a 62.56% increase over the same period last year.
November 09, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Xeris Biopharma Holdings reported improved Q3 earnings with reduced losses and sales exceeding estimates.
The company's improved earnings report, with reduced losses and sales exceeding estimates, is likely to have a positive impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100